Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China

Stock Information for Clearmind Medicine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clearmind Medicine Inc.

Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
Clearmind Medicine CEO Issues Letter to Shareholders
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
CSE Bulletin: Delist - Clearmind Medicine Inc. (CMND)
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.